Table 3 The role of sCD80 level in various chronic disease

SLE

0.29 (0.18–0.44) ng/mL (active SLE) and 0.28 (0.16–0.40) ng/mL (inactive SLE)

(plasma)

Elevated in SLE but has no correlation with disease activity.

[82]

Arthritis

15.98 ± 6.4 ng/ml (RA)

37.06 ± 8.2 ng/ml (osteoarthritis)

7.817 ± 5 ng/ml (other arthritis)

(synovial fluid)

Elevated in RA, osteoarthritis (OA), and other arthritis.

[103]

RA

> 0.22 ng/ml

(synovial fluid)

Elevated in synovial fluid of RA patients but not in serum.

[104]

NA

(serum)

Elevated in RA and correlated with treatment response.

[81]

Myasthenia Gravis

NA

(serum)

Increased in myasthenia gravis and correlated with treatment response.

[83]

AAV

NA

(serum)

Elevated in AAV and correlated with treatment response.

[85]

Asthma (pediatric)

0.36 (0.28–0.43) ng/mL

(plasma)

Increased in allergic asthma and correlated with IgE level.

[87]

0.3 (0.2–0.4) ng/mL

(plasma)

Highly elevated in acute asthma attack and correlated with corticosteroid treatment response.

[88]

Nephrotic syndrome

514.01 ± 62.6 ng/mL

(serum, rats)

152.48 ± 23.4 ng/mL

(urine, rats)

Elevated in serum and urine nephrotic syndrome rat. Urine sCD80 level is positively correlated with total cholesterol, protein urine, and sCTLA-4 urine but negatively correlated with serum albumin level.

[105]

MCD (pediatric)

14.6 ± 30.8 ng/g creatinine

(urine)

Increased in MCD and correlated with treatment response.

[106]

524 ± 86 ng/g creatinine

(urine)

Elevated in relapse MCD but not MCD in remission focal segmental glomerulosclerosis

[107]

Diabetic nephropathy

0.27 (0.20–0.41) ng/mL

(plasma)

Elevated in diabetic nephropathy also, correlated with fasting urine abumin:creatinine ratio.

[95]

Mycobacterium tuberculosis infection

NA

(pleural effusion fluid)

Elevated in pleural effusion fluid but not in serum TB patients. Has positive correlation with LDH level and lymphocyte percentage in pleural effusion fluid.

[89]

HBV infection

NA

(serum)

Decreased in chronic HBV infection, protective against liver cirrhosis.

[108]

NA

(serum)

Elevated in chronic HBV infection but does not correlate with AST nor ALT level.

[90]

Alcoholic hepatitis

9 pg/mL

(plasma)

Decreased in alcoholic hepatitis and correlated with disease activity, bacterial translocation, and inflammatory parameters.

[109]

HCC

NA

(plasma)

Increased in HCC after trans arterial chemoembolization (TACE) but not in HCC after Lenvatinib treatment.

[110]

≥ 82 pg/mL

(plasma)

Increased in HCC post treatment with sorafenib.

[111]

Hematology malignancy

0.02–3.75 ng/ml

(plasma)

Increased in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) but not in acute myeloid leukemia (AML) nor multiple myeloma (MM). Negatively correlated with prognosis, thrombocyte count, and hemoglobin level but positively correlated with leukocyte count in CLL.

[112]

Non-Hodgkin Lymphoma (NHL)

NA

(serum)

Elevated NHL especially CLL and small lymphocytic lymphoma (SLL) also correlated with poor prognosis.

[113]

Soft tissue tumor

566.8 pg/mL (benign) and 609.7 pg/mL (sarcoma)

(serum)

Negatively correlated with metastasis-free survival in benign soft tissue tumor and soft tissue sarcoma.

[32]

Non-small cell lung carcinoma (NSCLC)

6.32 pg/mL

(serum)

Elevated in NSCLC but does not correlate with disease severity.

[114]

65.11 pg/mL (preinvasive) and 132.06–176.76 pg/mL (invasive)

(plasma)

Elevated in invasive NSCLC compared with preinvasive NSCLC also correlated with invasive disease occurrence.

[115]

Uveal melanoma

NA

(serum)

Increase 1.3 fold in metastasis uveal melanoma during anti-PD-1 treatment.

[94]